The estimated Net Worth of David Scott Jones is at least $1 Million dollars as of 9 February 2024. Mr Jones owns over 9,967 units of EyePoint Pharmaceuticals Inc stock worth over $399,262 and over the last 5 years he sold EYPT stock worth over $0. In addition, he makes $604,045 as Sr. VP & Chief Commercial Officer at EyePoint Pharmaceuticals Inc.
Mr has made over 11 trades of the EyePoint Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 9,967 units of EYPT stock worth $81,929 on 9 February 2024.
The largest trade he's ever made was exercising 41,050 units of EyePoint Pharmaceuticals Inc stock on 30 June 2020 worth over $337,431. On average, Mr trades about 9,567 units every 78 days since 2019. As of 9 February 2024 he still owns at least 48,572 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Mr Jones stock trades at the bottom of the page.
David Scott Jones is the Sr. VP & Chief Commercial Officer at EyePoint Pharmaceuticals Inc.
As the Sr. VP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc, the total compensation of Mr Jones at EyePoint Pharmaceuticals Inc is $604,045. There are 6 executives at EyePoint Pharmaceuticals Inc getting paid more, with Nancy Lurker having the highest compensation of $2,079,780.
Mr Jones is 54, he's been the Sr. VP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc since . There are 16 older and 2 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... und Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: